<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Norepinephrine (noradrenaline): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Norepinephrine (noradrenaline): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Norepinephrine (noradrenaline): Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9709" href="/d/html/9709.html" rel="external">see "Norepinephrine (noradrenaline): Drug information"</a> and <a class="drug drug_patient" data-topicid="12090" href="/d/html/12090.html" rel="external">see "Norepinephrine (noradrenaline): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F202403"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Levophed</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867717"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Levophed</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1054472"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Adrenergic Agonist Agent</span>;</li>
<li>
<span class="list-set-name">Alpha-Adrenergic Agonist</span>;</li>
<li>
<span class="list-set-name">Sympathomimetic</span></li></ul></div>
<div class="block don drugH1Div" id="F53462524"><span class="drugH1">Dosing: Neonatal</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> Dose stated in terms of <b>norepinephrine base</b>.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1cc20a87-1535-4406-8f0f-be1e12bb7154">Septic shock, refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Septic shock, refractory:</b> Limited data available: Preterm and term neonates: Continuous IV infusion: Usual initial dose: 0.02 to 0.1 mcg/kg/minute; titrate to desired effect; usual maximum dose: 1 to 2 mcg/kg/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31010560','lexi-content-ref-Domonoske.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31010560','lexi-content-ref-Domonoske.1'])">Ref</a></span>). Studies in neonates (GA ≥23 weeks) with refractory septic shock show norepinephrine improves blood pressure and may improve organ perfusion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28992392','lexi-content-ref-27744568','lexi-content-ref-18177443']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28992392','lexi-content-ref-27744568','lexi-content-ref-18177443'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="39cf217a-86f4-4813-bea9-28f9108f7189">Circulatory failure; refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Circulatory failure (pulmonary hypertension, persistent [PPHN] induced); refractory: </b>Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">GA ≥35 weeks: Continuous IV infusion: Usual initial dose: 0.02 to 0.5 mcg/kg/minute; titrate to desired effect; usual maximum dose: 1.5 mcg/kg/minute; doses up to 3.3 mcg/kg/minute have been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9342718','lexi-content-ref-18534241']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9342718','lexi-content-ref-18534241'])">Ref</a></span>). Usual dose range: 0.02 to 1 mcg/kg/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31010560']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31010560'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F202422"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> Dose stated in terms of <b>norepinephrine base</b>.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c75bd2c4-3b1d-4e1b-b983-93eb5c096819">Hypotension/shock, fluid-resistant</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypotension/shock, fluid-resistant: </b>Infants, Children, and Adolescents: Continuous IV or intraosseous infusion: Initial: 0.05 to 0.1 mcg/kg/minute; titrate to desired effect; usual maximum dose: 2 mcg/kg/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31871244','lexi-content-ref-28509730','lexi-content-ref-Bishop.1','lexi-content-ref-20956230','lexi-content-ref-Park.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31871244','lexi-content-ref-28509730','lexi-content-ref-Bishop.1','lexi-content-ref-20956230','lexi-content-ref-Park.1'])">Ref</a></span>); higher doses have been reported in the literature (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22568565']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22568565'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51131255"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51131256"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F202407"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9709" href="/d/html/9709.html" rel="external">see "Norepinephrine (noradrenaline): Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="26fed829-e145-4f6f-b3e9-04e9d8199da8">Cardiogenic shock</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cardiogenic shock:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Optimal goal of therapy not well established, but typically titrate to maintain end-organ perfusion. Institutional protocols may vary with weight-based or non-weight-based dose regimens (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28923988','lexi-content-ref-Hochman.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28923988','lexi-content-ref-Hochman.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Continuous infusion:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Weight-based dosing: IV: </b>Initial: 0.05 mcg/<b>kg</b>/minute; titrate based on clinical end point (eg, BP, end-organ perfusion); usual dosage range: 0.05 to 0.4 mcg/<b>kg</b>/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28923988','lexi-content-ref-29976291']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28923988','lexi-content-ref-29976291'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Non–weight-based dosing (based on ~80 kg patient): IV:</b> Initial: 5 mcg/minute; titrate based on clinical end point (eg, BP, end-organ perfusion); usual dosage range: 5 to 30 mcg/minute (doses calculated and rounded for an 80 kg patient based on weight-based dosing using the referenced sources (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28923988','lexi-content-ref-29976291']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28923988','lexi-content-ref-29976291'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="318d1b08-1252-4f77-9525-de1f8d859874">Hepatorenal syndrome type 1 or acute kidney injury, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatorenal syndrome type 1 or acute kidney injury, treatment (alternative agent) (off-label use): Note</b>: Alternative to terlipressin. Use in combination with albumin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33942342']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33942342'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Continuous infusion</b>
<b>: </b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Non–weight-based dosing: IV:</b> Initial: 5 to 8 mcg/minute; dose may be increased every 4 hours based on clinical end points (eg, increase mean arterial pressure of ~10 mm Hg from baseline, improved urine output); maximum dose: 10 mcg/minute non-ICU; 50 mcg/minute in ICU (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33942342','lexi-content-ref-12143045','lexi-content-ref-34276366','lexi-content-ref-33837624','lexi-content-ref-18557715','lexi-content-ref-22322237']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33942342','lexi-content-ref-12143045','lexi-content-ref-34276366','lexi-content-ref-33837624','lexi-content-ref-18557715','lexi-content-ref-22322237'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="eff13f76-62c8-40ba-b4f6-114731b188b2">Post–cardiac arrest shock</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Post–cardiac arrest shock:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Optimal goal of therapy not well established, but typically titrate to mean arterial BP (MAP) &gt;65 mm Hg and preferably systolic BP of 80 to 100 mm Hg to optimize cerebral and end-organ perfusion. Institutional protocols may vary with weight-based or non-weight-based dose regimens (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26472996','lexi-content-ref-Elmer.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26472996','lexi-content-ref-Elmer.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Continuous infusion:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Weight-based dosing: IV: </b> Initial: 0.05 to 0.15 mcg/<b>kg</b>/minute; titrate based on clinical end points (eg, MAP, end-organ perfusion); usual dosing range: 0.05 to 1 mcg/<b>kg</b>/minute; maximum dose range for refractory shock: 1 to 3.3 mcg/<b>kg</b>/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20956225','lexi-content-ref-Elmer.1','lexi-content-ref-15343024','lexi-content-ref-Manaker.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20956225','lexi-content-ref-Elmer.1','lexi-content-ref-15343024','lexi-content-ref-Manaker.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Non–weight-based dosing (based on ~80 kg patient): IV:</b> Initial: 5 to 15 mcg/minute; titrate based on clinical end points (eg, MAP, end-organ perfusion); usual dosing range: 5 to 80 mcg/minute; maximum dose range for refractory shock: 80 to 250 mcg/minute (doses calculated and rounded for an 80 kg patient based on weight-based dosing using the referenced sources (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20956225','lexi-content-ref-Elmer.1','lexi-content-ref-15343024','lexi-content-ref-Manaker.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20956225','lexi-content-ref-Elmer.1','lexi-content-ref-15343024','lexi-content-ref-Manaker.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="25b97a8f-8e14-4a06-b25d-78c7f5328beb">Septic shock and other vasodilatory shock states</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Septic shock and other vasodilatory shock states:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> In general, used to maintain goal MAP (eg, ~65 mm Hg); consider use if patient is in shock or has hypoperfusion during or after fluid resuscitation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32049269','lexi-content-ref-29976291','lexi-content-ref-34605781']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32049269','lexi-content-ref-29976291','lexi-content-ref-34605781'])">Ref</a></span>). Institutional protocols may vary with weight-based or non-weight-based dose regimens.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Continuous infusion:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Weight-based dosing: IV: </b> Initial: 0.05 to 0.15 mcg/<b>kg</b>/minute; titrate to goal MAP; usual dose range: 0.025 to 1 mcg/<b>kg</b>/minute; maximum dose range for refractory shock: 1 to 3.3 mcg/<b>kg</b>/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20200382','lexi-content-ref-15343024','lexi-content-ref-21097695','lexi-content-ref-Manaker.1','lexi-content-ref-2389659','lexi-content-ref-18305265']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20200382','lexi-content-ref-15343024','lexi-content-ref-21097695','lexi-content-ref-Manaker.1','lexi-content-ref-2389659','lexi-content-ref-18305265'])">Ref</a></span>). <b>Note:</b> While available data describe a wide range of initial dosing (0.01 to 0.5 mcg/kg/minute), initial dosing provided is a reasonable starting point for most patients.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Non–weight-based dosing (based on ~80 kg patient): IV: </b> Initial: 5 to 15 mcg/minute; titrate to goal MAP; usual dose range: 2 to 80 mcg/minute; maximum dose range for refractory shock: 80 to 250 mcg/minute (doses calculated and rounded for an 80 kg patient based on weight-based dosing using the referenced sources (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20200382','lexi-content-ref-15343024','lexi-content-ref-21097695','lexi-content-ref-Manaker.1','lexi-content-ref-2389659','lexi-content-ref-18305265']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20200382','lexi-content-ref-15343024','lexi-content-ref-21097695','lexi-content-ref-Manaker.1','lexi-content-ref-2389659','lexi-content-ref-18305265'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990565"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b> No dosage adjustment necessary for any degree of kidney impairment (only small amount excreted by kidney unchanged) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.dor']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.dor'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Augmented renal clearance (measured urinary CrCl ≥130 mL/minute/1.73 m<sup>2</sup>):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Augmented renal clearance (ARC) is a condition that occurs in certain critically ill patients without organ dysfunction and with normal serum creatinine concentrations. Younger patients (&lt;55 years of age) admitted post trauma or major surgery are at highest risk for ARC, as well as those with sepsis, burns, or hematologic malignancies. An 8- to 24-hour measured urinary CrCl is necessary to identify these patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29441476','lexi-content-ref-20000886']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29441476','lexi-content-ref-20000886'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.dor']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.dor'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly</b>): Likely to be dialyzable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-4004425']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-4004425'])">Ref</a></span>)<b>:</b> No supplemental dose or dosage adjustment necessary since norepinephrine is titrated to clinical targets (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.dor']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.dor'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.dor']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.dor'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> Unlikely to be significantly dialyzable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8181293','lexi-content-ref-9120109']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8181293','lexi-content-ref-9120109'])">Ref</a></span>): No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.dor']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.dor'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.dor']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.dor'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50987913"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F202378"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Bradycardia, cardiac arrhythmia, cardiomyopathy (stress), peripheral vascular insufficiency</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Anxiety, transient headache</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Peripheral gangrene, peripheral ischemia (digital [Daroca-Pérez 2017])</p></div>
<div class="block coi drugH1Div" id="F202391"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">There are no contraindications listed in the US manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Hypotension from hypovolemia except as an emergency measure to maintain coronary and cerebral perfusion until volume could be replaced; mesenteric or peripheral vascular thrombosis unless it is a lifesaving procedure; during anesthesia with cyclopropane or halothane anesthesia.</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block war drugH1Div" id="F202375"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Extravasation: Vesicant; ensure proper needle or catheter placement prior to and during infusion. Avoid extravasation; infuse into a large vein if possible. Avoid infusion into leg veins. Monitor IV site closely. If extravasation occurs, infiltrate the area with diluted phentolamine (5 to 10 mg in 10 mL saline in adult patients) with a fine hypodermic needle. Phentolamine should be administered as soon as possible after extravasation is noted to prevent sloughing/necrosis (Stefanos 2023).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hypovolemia: Address hypovolemia before initiating therapy; patients who are hypotensive from hypovolemia may experience severe peripheral and visceral vasoconstriction, decreased renal perfusion and reduced urine output, tissue hypoxia, lactic acidosis, and reduced systemic blood flow despite normal BP.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypoxia/hypercarbia: Use in patients with profound hypoxia or hypercarbia may produce ventricular tachycardia or fibrillation; use with extreme caution.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Sodium metabisulfite: Product may contain sodium metabisulfite. Use caution in patients with asthma or a sulfite allergy; allergic-type reactions, including anaphylactic symptoms and life-threatening asthmatic episodes, may occur.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Abrupt discontinuation: Gradually reduce infusion rate while expanding blood volume with IV fluids during discontinuation of therapy; severe hypotension may occur with abrupt discontinuation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Assure adequate circulatory volume to minimize need for vasoconstrictors. Avoid hypertension; monitor BP closely and adjust infusion rate. Avoid in patients with mesenteric or peripheral vascular thrombosis; use may increase ischemia and extend the area of infarction.</p></div>
<div class="block dosfc drugH1Div" id="F56409139"><span class="drugH1">Dosage Forms Considerations</span>
<p style="text-indent:0em;display:inline">Norepinephrine dosage is stated in terms of norepinephrine base. Although the IV product vial designates the contents as norepinephrine bitartrate, the actual concentration shown is in terms of norepinephrine base 1 mg/mL.</p></div>
<div class="block foc drugH1Div" id="F202385"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Levophed: 1 mg/mL (4 mL) [contains sodium metabisulfite]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1 mg/mL (4 mL); 16 mg/250 mL in NaCl 0.9% (250 mL); 4 mg/250 mL in NaCl 0.9% (250 mL); 8 mg/250 mL in NaCl 0.9% (250 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1 mg/mL (4 mL); 16 mg/250 mL in Dextrose 5% (250 mL); 4 mg/250 mL in Dextrose 5% (250 mL); 8 mg/250 mL in Dextrose 5% (250 mL)</p></div>
<div class="block geq drugH1Div" id="F202371"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16323542"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Levophed Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg/mL (per mL): $6.74</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Norepinephrine Bitartrate Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg/mL (per mL): $0.99 - $5.69</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Norepinephrine-Dextrose Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4MG/250ML 5% (per mL): $0.12</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">8MG/250ML 5% (per mL): $0.17</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">16MG/250ML 5% (per mL): $0.34</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Norepinephrine-Sodium Chloride Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4MG/250ML 0.9% (per mL): $0.18</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">8MG/250ML 0.9% (per mL): $0.24</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">16MG/250ML 0.9% (per mL): $0.38</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867718"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Levophed: 1 mg/mL (4 mL) [contains sodium metabisulfite]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1 mg/mL (4 mL); 4 mg/250 mL in Dextrose 5% (250 mL); 8 mg/250 mL in Dextrose 5% (250 mL)</p></div>
<div class="block admp drugH1Div" id="F52613442"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral: Continuous IV infusion: Administer as a continuous infusion via an infusion pump. Vials must be diluted prior to administration; premixed IV solutions (16 mcg/mL and 32 mcg/mL) are available. Central line administration is preferred; extravasation may cause severe ischemic necrosis. If central line is not available, may administer for a short duration through a peripheral IV catheter placed in a large vein or via intraosseous access using a more dilute solution or with a second carrier fluid (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28509730','lexi-content-ref-32032273']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28509730','lexi-content-ref-32032273'])">Ref</a></span>); frequent monitoring of the IV catheter site is recommended to rapidly identify extravasation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24420913']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24420913'])">Ref</a></span>). <b>Note: </b>Refer to institutional policies and procedures; catheter placement/size and vasopressor concentration may vary depending on institution. Do not administer sodium bicarbonate (or any alkaline solution) through an IV line containing norepinephrine; inactivation of norepinephrine may occur (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31871244']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31871244'])">Ref</a></span>). Avoid abrupt withdrawal; reduce infusion flow rate slowly.</p>
<p style="text-indent:0em;margin-left:2em;">Rate of infusion (mL/hour) = dose (mcg/kg/minute) x weight (kg) x 60 minutes/hour divided by the concentration (mcg/mL)</p>
<p style="text-indent:-2em;margin-left:2em;">Vesicant; ensure proper needle or catheter placement prior to and during infusion; avoid extravasation. If extravasation occurs, stop infusion immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do <b>NOT</b> flush the line); remove needle/cannula; elevate extremity. Initiate phentolamine (or alternative) antidote (see Management of Drug Extravasations for more details). Apply dry warm compresses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15192356','lexi-content-ref-24420913']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15192356','lexi-content-ref-24420913'])">Ref</a></span>).</p></div>
<div class="block adm drugH1Div" id="F202388"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b>
<b>Administer as a continuous infusion via an infusion pump.</b> Dilute vials prior to use; premixed solutions are also available for IV infusion. Central line administration is preferred; extravasation may cause severe ischemic necrosis. If central line is not available, may administer for a short duration (&lt;72 hours) through a peripheral IV catheter placed in a large vein at a proximal site (eg, in or proximal to antecubital fossa). Frequent monitoring of the IV catheter site is recommended to rapidly identify extravasation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26014852','lexi-content-ref-28073314','lexi-content-ref-29110979','lexi-content-ref-32925324','lexi-content-ref-34605781','lexi-content-ref-31698544']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26014852','lexi-content-ref-28073314','lexi-content-ref-29110979','lexi-content-ref-32925324','lexi-content-ref-34605781','lexi-content-ref-31698544'])">Ref</a></span>). Refer to institutional policies and procedures; catheter placement/size and vasopressor concentration may vary depending on institution. Administration through midline catheters may also be an option (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33049486']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33049486'])">Ref</a></span>). Do not administer sodium bicarbonate (or any alkaline solution) through an IV line containing norepinephrine; inactivation of norepinephrine may occur. Avoid abrupt withdrawal; reduce infusion flow rate slowly.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">Vesicant; ensure proper needle or catheter placement prior to and during infusion; avoid extravasation.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Extravasation management:</b> If extravasation occurs, stop infusion immediately; leave cannula/needle in place temporarily but do <b>NOT</b> flush the line; gently aspirate extravasated solution, then remove needle/cannula; elevate extremity; apply dry warm compresses; initiate phentolamine (or alternative) antidote (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36938775']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36938775'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Phentolamine:</i>
<b>SUBQ: </b>Dilute 5 to 10 mg in 10 mL NS and administer into extravasation site as soon as possible after extravasation; if IV catheter remains in place, administer initial dose IV through infiltrated catheter; may repeat in 60 minutes if patient remains symptomatic (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36938775']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36938775'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Alternatives to phentolamine:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Nitroglycerin topical 2% ointment: Apply a 1-inch strip to the site of ischemia to cover the affected area; may repeat every 8 hours as necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36938775']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36938775'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Terbutaline:</p>
<p style="text-indent:-2em;margin-left:8em;">Large extravasations: <b>SUBQ: </b>Infiltrate affected extravasation area with terbutaline 1 mg using a solution of terbutaline 1 mg diluted in 10 mL NS; may repeat dose after 15 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36938775']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36938775'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Small extravasations: <b>SUBQ: </b>Infiltrate affected extravasation area with terbutaline 0.5 mg using a solution of terbutaline 1 mg diluted in 1 mL NS; may repeat dose after 15 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36938775']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36938775'])">Ref</a></span>).</p></div>
<div class="block uicn drugH1Div" id="F14473013"><span class="drugH1">Usual Infusion Concentrations: Neonatal</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Premixed solutions are available.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV infusion:</b> 16 <b>mcg</b>/mL.</p></div>
<div class="block uicp drugH1Div" id="F14473012"><span class="drugH1">Usual Infusion Concentrations: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Premixed solutions are available.</p>
<p style="text-indent:-2em;margin-left:2em;">IV infusion: 16 <b>mcg</b>/mL, 32 <b>mcg</b>/mL, <b>or</b> 64 <b>mcg</b>/mL.</p></div>
<div class="block sts drugH1Div" id="F202398"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Premixed solution in D5W:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Refrigerated product: Store in protective overwrap at 2°C to 8°C (36°F to 46°F); protect from light. Once removed from refrigerator, may be stored in overwrap at room temperature (up to 25°C [77°F]) for up to 90 days and the overwrap should be marked to indicate the revised 90-day expiration date. Do not return product to the refrigerator after it has been stored at room temperature. Once overwrap is removed, may be stored for up to 30 days at room temperature.</p>
<p style="text-indent:-2em;margin-left:4em;">Room temperature product: Store in protective overwrap at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Protect from light. Once overwrap is removed, may be stored for up to 30 days at room temperature.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Premixed solution in NS: </b>Store in protective overwrap at 20°C to 25°C (68°F to 77°F). Protect from light. Once overwrap is removed, may be stored for up to 7 days at room temperature.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Vials:</b> Store intact vials in original container at 20°C to 25°C (68°F to 77°F); excursion permitted to 15°C to 30°C (59°F to 86°F). Diluted solution may be stored at room temperature for up to 24 hours. Protect from light.</p></div>
<div class="block usep drugH1Div" id="F53568057"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of severe, acute hypotension (FDA approved in adults); has also been used for shock and in neonates with persistent pulmonary hypertension (PPHN)-induced circulatory failure.</p></div>
<div class="block mst drugH1Div" id="F5174558"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Levophed may be confused with levofloxacin</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error. </p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299773"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of COMT</p></div>
<div class="block dri drugH1Div" id="F202380"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alpha1-Blockers: May diminish the vasoconstricting effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize Alpha1-Blocker vasodilation.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atomoxetine: May enhance the hypertensive effect of Sympathomimetics. Atomoxetine may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Azosemide: May diminish the therapeutic effect of Norepinephrine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benzylpenicilloyl Polylysine: Alpha-/Beta-Agonists may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Consider use of a histamine skin test as a positive control to assess a patient's ability to mount a wheal and flare response.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bretylium: May enhance the therapeutic effect of Alpha-/Beta-Agonists (Direct-Acting).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromocriptine: May enhance the hypertensive effect of Alpha-/Beta-Agonists. Management: Consider alternatives to this combination when possible. If combined, monitor for hypertension and tachycardia, and do not coadminister these agents for more than 10 days.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: May enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloroprocaine (Systemic): May enhance the hypertensive effect of Alpha-/Beta-Agonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: May diminish the therapeutic effect of Alpha-/Beta-Agonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cocaine (Topical): May enhance the hypertensive effect of Sympathomimetics. Management: Consider alternatives to use of this combination when possible. Monitor closely for substantially increased blood pressure or heart rate and for any evidence of myocardial ischemia with concurrent use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COMT Inhibitors: May increase the serum concentration of COMT Substrates.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxofylline: Sympathomimetics may enhance the adverse/toxic effect of Doxofylline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Droxidopa: Norepinephrine may enhance the hypertensive effect of Droxidopa. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates): May enhance the vasoconstricting effect of Alpha-/Beta-Agonists.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Furosemide: May diminish the therapeutic effect of Norepinephrine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Guanethidine: May enhance the arrhythmogenic effect of Sympathomimetics. Guanethidine may enhance the hypertensive effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hyaluronidase: May enhance the vasoconstricting effect of Alpha-/Beta-Agonists. Management: Do not use hyaluronidase to enhance the dispersion or absorption of alpha-/beta-agonists. Use of hyaluronidase for other purposes in patients receiving alpha-/beta-agonists may be considered as clinically indicated.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inhalational Anesthetics: May enhance the arrhythmogenic effect of Norepinephrine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kratom: May enhance the adverse/toxic effect of Sympathomimetics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levothyroxine: May enhance the adverse/toxic effect of Sympathomimetics. Specifically, the risk of coronary insufficiency may be increased in patients with coronary artery disease. Levothyroxine may enhance the therapeutic effect of Sympathomimetics. Sympathomimetics may enhance the therapeutic effect of Levothyroxine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Consider initial dose reductions of sympathomimetic agents, and closely monitor for enhanced blood pressure elevations, in patients receiving linezolid.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lisuride: May enhance the hypertensive effect of Alpha-/Beta-Agonists.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Monoamine Oxidase Inhibitors: May enhance the hypertensive effect of Norepinephrine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ozanimod: May enhance the hypertensive effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pergolide: May enhance the hypertensive effect of Alpha-/Beta-Agonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the tachycardic effect of Alpha-/Beta-Agonists. Serotonin/Norepinephrine Reuptake Inhibitors may enhance the vasopressor effect of Alpha-/Beta-Agonists. Management: If possible, avoid coadministration of direct-acting alpha-/beta-agonists and serotonin/norepinephrine reuptake inhibitors. If coadministered, monitor for increased sympathomimetic effects (eg, increased blood pressure, chest pain, headache).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Solriamfetol: Sympathomimetics may enhance the hypertensive effect of Solriamfetol. Sympathomimetics may enhance the tachycardic effect of Solriamfetol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Spironolactone: May diminish the vasoconstricting effect of Alpha-/Beta-Agonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tedizolid: May enhance the hypertensive effect of Sympathomimetics. Tedizolid may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tricyclic Antidepressants: May enhance the vasopressor effect of Alpha-/Beta-Agonists. Management: Avoid, if possible, the use of alpha-/beta-agonists in patients receiving tricyclic antidepressants. If combined, monitor for evidence of increased pressor effects and consider reductions in initial dosages of the alpha-/beta-agonist.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vasopressin: Alpha-/Beta-Agonists (Direct-Acting) may enhance the hypertensive effect of Vasopressin. The effect of other hemodynamic parameters may also be enhanced. <i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F13376222"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Norepinephrine is an endogenous catecholamine and crosses the placenta (Minzter 2010; Wang 1999).</p>
<p style="text-indent:0em;margin-top:2em;">Medications used for the treatment of cardiac arrest in pregnancy are the same as in the non-pregnant woman. Appropriate medications should not be withheld due to concerns of fetal teratogenicity. Norepinephrine use during the post-resuscitation phase may be considered; however, the effects of vasoactive medications on the fetus should also be considered. Doses and indications should follow current Advanced Cardiovascular Life Support guidelines (Jeejeebhoy [AHA] 2015).</p></div>
<div class="block mopp drugH1Div" id="F53568051"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Blood pressure (or mean arterial pressure), heart rate, cardiac output (as appropriate), intravascular volume status, pulmonary capillary wedge pressure (as appropriate); urine output, peripheral perfusion; monitor infusion site closely.</p>
<p style="text-indent:0em;margin-top:2em;">Consult individual institutional policies and procedures.</p></div>
<div class="block pha drugH1Div" id="F202374"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Stimulates beta<sub>1</sub>-adrenergic receptors and alpha-adrenergic receptors causing increased contractility and heart rate as well as vasoconstriction, thereby increasing systemic blood pressure and coronary blood flow; clinically, alpha effects (vasoconstriction) are greater than beta effects (inotropic and chronotropic effects)</p></div>
<div class="block phk drugH1Div" id="F202390"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Very rapid acting.</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: Vasopressor: 1 to 2 minutes.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 8.8 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 25% mainly albumin with smaller extent to prealbumin and alpha 1-acid glycoprotein.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Via catechol-o-methyltransferase and monoamine oxidase.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Mean: ~2.4 minutes.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: Steady state: 5 minutes.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (as inactive metabolites; small amounts as unchanged drug).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6038708"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Levophed | Noradrenaline</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Noradrenalina biol | Noradrenalina phoroneus | Noradrenalina richet</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Noradrenalin Aguettant | Noradrenalin hospira | Noradrenalin kabi | Noradrenalin mayrhofer | Noradrenalin orpha | Sinora</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Levophed | Noradrenaline bnm | Noradrenaline juno | Noradrenaline myx | Noralin</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Hyponor | Levofed</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Levophed | Noradrenaline aguettant | Norepine</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Norepinephrine sopharma</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Epikabi | Hemitartarato de Norepinefrina | Hyponor | Levophed | Noradrem | Noradren | Norepine | Norepinefrina</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Noradrenaline sintetica</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Norepinefrina</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">ADS-Noltron | Levophed | Norepinefrina | Pridam</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Noradrenalin | Norepinephrine kabi | Norepinephrine kalceks | Sinora</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Noradrenalin Aguettant | Noradrenalin kabi | Norepinephrin kalceks | Sinora</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Norepinefrina bitartrato | Norepinefrina vitalis</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Biemefrin | Cardenor | Noradren | Noradrenalin | Noradrenaline | Norepine | Norepinephrine kabi | Norepinephrine kalceks | Norepinephrine sintetica | Norepinephrine sopharma | Sinora</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Levophrine</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Noradrenalina Braun | Noradrenalina Combino pharm | Noradrenalina kalceks | Noradrenalina Normon | Norages</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Nor adrenalin | Noradrenalin abcur | Noradrenalin Aguettant | Noradrenalin hospira | Noradrenalin kalceks | Noradrenaline sintetica</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Noradrenaline aguettant | Noradrenaline Hospira | Noradrenaline Merck | Noradrenaline PCH | Noradrenaline renaudin</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Levophed | Noradrenaline | Sinora</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Noradren</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Levophed | Noradrenaline sintetica</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Noradrenalin ligula pharma</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Noradrenaline kabi | Norepinephrine kalceks | Sinora</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Epinor | Guprin | Levophed | Norepinephrine | Raivas | Vascon</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Levophed | Noradrenaline | Noradrenaline (Norepinephrine)</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Adrenor | Infunor | Norad | Noradol | Noradria | Norepirin</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Noradrenalina tartrato | Noradrenalina tartrato aguettant</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Levophed | Noradrenaline</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Levophed | Nor adrenalin</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Levophed | Q phrine</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Levophed | Noradrenaline | Noradrenaline aguettant</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Noradrenaline tartrate renaudin</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Levonor | Levophed | Norad 4 | Noradren | Noradrenaline (tartrate) aguettant | Norages | Norepine | Norepinephrine kalceks | Norepinephrine sintetica | Norepinephrine sopharma</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Levophed</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Norepinephrine kabi | Norepinephrine kalceks | Norepinephrine sopharma | Sinora</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Afhimad | Boguefren | Envetim | Naretia | Necsol | Softamicid</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Biemefrin | Cardiamed | Levophed</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Noradrenaline Hospira | Noradrenaline kabi | Noradrenaline kalceks | Norepinefrine | Sinora</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Noradrenalin | Noradrenalin abcur | Noradrenalin Aguettant | Noradrenalin macure | Noradrenalin sintetica</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Biomed noradrenaline | Levophed | Noradrenaline</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Norepinefrina | Norepinefrina northia</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Hypoact | Levophed | Mephrin | Norepin | Norphed | Northix | Sandine</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Adrenor | Cardenor | Noradrenalin kalceks | Noradrenaline kabi | Norepinephrine | Sinora</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Levophed | Norepinephrine</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">L noradrenalina braun | Noradrenalina | Noradrenalina basi</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Norepinefrina northia</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Levophed | Noradrenaline Aguettant | Veraline</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Noradrenalina amdipharm</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Noradrenaline | Noradrenaline aguettant | Noradrenaline kabi | Norepinephrine</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Epinor | Levophed | Nevoleen | Noradren</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Noradrenalin abcur | Noradrenalin Aguettant | Noradrenalin fresenius kabi | Noradrenalin hospira | Noradrenalin kalceks | Noradrenaline sintetica</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Levophed</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Noradrenalin sintetica</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Norepinephrine kabi | Norepinephrine kalceks | Sinora</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Levophed | N epi | Noradrenaline aguettant | Norene | Norpin</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Noradrenaline | Noradrenaline medis | Noradrenaline mylan | Noradrenaline renaudin | Noradrenaline saiph | Noraline</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Adrenor | Biemefrin | Cardenor | Epinor | Forefrin | Nefrinor | Noreprin | Seladrenalin | Stenor | Steradin | Turktipsan noradrenalin</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Levophed bitartrat | Nobify | Noradrec | Norepine | Norepinephrine</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Adrenor | N epi</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Norad</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Fioritina | Noradrenalina novophar | Norepinefrina northia</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Sinora</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-27969574">
<a name="27969574"></a>Adams C, Tucker C, Allen B, et al. Disparities in hemodynamic resuscitation of the obese critically ill septic shock patient. <i>J Crit Care</i>. 2017;37:219-223. doi:10.1016/j.jcrc.2016.10.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norepinephrine-noradrenaline-pediatric-drug-information/abstract-text/27969574/pubmed" id="27969574" target="_blank">27969574</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ASHP.1">
<a name="ASHP.1"></a>American Society of Health-System Pharmacists (ASHP). Pediatric continuous infusion standards. Available at https://www.ashp.org/-/media/assets/pharmacy-practice/s4s/docs/Pediatric-Infusion-Standards.ashx. Updated January 2021. Accessed February 9, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6859687">
<a name="6859687"></a>Aron DC, Bravo EL, Kapcala LP. Erroneous Plasma Norepinephrine Levels With Radioimmunoassay. <i>Ann Intern Med</i>. 1983;98(6):1023.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norepinephrine-noradrenaline-pediatric-drug-information/abstract-text/6859687/pubmed" id="6859687" target="_blank">6859687</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-expert.1">
<a name="expert.1"></a>Based on expert opinion.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8181293">
<a name="8181293"></a>Bellomo R, McGrath B, Boyce N. Effect of continuous venovenous hemofiltration with dialysis on hormone and catecholamine clearance in critically ill patients with acute renal failure. <i>Crit Care Med</i>. 1994;22(5):833-837. doi:10.1097/00003246-199405000-00020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norepinephrine-noradrenaline-pediatric-drug-information/abstract-text/8181293/pubmed" id="8181293" target="_blank">8181293</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33942342">
<a name="33942342"></a>Biggins SW, Angeli P, Garcia-Tsao G, et al. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 practice guidance by the American Association for the Study of Liver Diseases. <i>Hepatology</i>. 2021;74(2):1014-1048. doi:10.1002/hep.31884<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norepinephrine-noradrenaline-pediatric-drug-information/abstract-text/33942342/pubmed" id="33942342" target="_blank">33942342</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29441476">
<a name="29441476"></a>Bilbao-Meseguer I, Rodríguez-Gascón A, Barrasa H, Isla A, Solinís MÁ. Augmented renal clearance in critically ill patients: a systematic review. <i>Clin Pharmacokinet</i>. 2018;57(9):1107-1121. doi:10.1007/s40262-018-0636-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norepinephrine-noradrenaline-pediatric-drug-information/abstract-text/29441476/pubmed" id="29441476" target="_blank">29441476</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bishop.1">
<a name="Bishop.1"></a>Bishop NB, Greenwald BM, Notterman DA. Pharmacology of the cardiovascular system. In: Fuhrman B, Zimmerman J, eds. <i>Pediatric Critical Care</i>. 5th ed. Elsevier Health; 2016: 352-379.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19325359">
<a name="19325359"></a>Brierley J, Carcillo JA, Choong K, et al. Clinical Practice Parameters for Hemodynamic Support of Pediatric and Neonatal Septic Shock: 2007 Update from the American College of Critical Care Medicine. <i>Crit Care Med</i>. 2009;37(2):666-688.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norepinephrine-noradrenaline-pediatric-drug-information/abstract-text/19325359/pubmed" id="19325359" target="_blank">19325359</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26472996">
<a name="26472996"></a>Callaway CW, Donnino MW, Fink EL, et al. Part 8: post-cardiac arrest care: 2015 American Heart Association guidelines update for cardiopulmonary resuscitation and emergency cardiovascular care. <i>Circulation</i>. 2015;132(18)(suppl 2):S465-S482. doi:10.1161/CIR.0000000000000262<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norepinephrine-noradrenaline-pediatric-drug-information/abstract-text/26472996/pubmed" id="26472996" target="_blank">26472996</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26014852">
<a name="26014852"></a>Cardenas-Garcia J, Schaub KF, Belchikov YG, Narasimhan M, Koenig SJ, Mayo PH. Safety of peripheral intravenous administration of vasoactive medication. <i>J Hosp Med</i>. 2015;10(9):581-585. doi:10.1002/jhm.2394<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norepinephrine-noradrenaline-pediatric-drug-information/abstract-text/26014852/pubmed" id="26014852" target="_blank">26014852</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6248784">
<a name="6248784"></a>Cryer PE. Physiology and Pathophysiology of the Human Sympathoadrenal Neuroendocrine System. <i>N Engl J Med</i>. 1980;303(8):436-444.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norepinephrine-noradrenaline-pediatric-drug-information/abstract-text/6248784/pubmed" id="6248784" target="_blank">6248784</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28781738">
<a name="28781738"></a>Daroca-Pérez R, Carrascosa MF. Digital necrosis: a potential risk of high-dose norepinephrine. <i>Ther Adv Drug Saf</i>. 2017;8(8):259-261.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norepinephrine-noradrenaline-pediatric-drug-information/abstract-text/28781738/pubmed" id="28781738" target="_blank">28781738</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28509730">
<a name="28509730"></a>Davis AL, Carcillo JA, Aneja RK, et al. American College of Critical Care Medicine clinical practice parameters for hemodynamic support of pediatric and neonatal septic shock. <i>Crit Care Med</i>. 2017;45(6):1061-1093.doi: 10.1097/CCM.0000000000002425.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norepinephrine-noradrenaline-pediatric-drug-information/abstract-text/28509730/pubmed" id="28509730" target="_blank">28509730</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20200382">
<a name="20200382"></a>De Backer D, Biston P, Devriendt J, et al. Comparison of dopamine and norepinephrine in the treatment of shock. <i>N Engl J Med</i>. 2010;362(9):779-789. doi:10.1056/NEJMoa0907118<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norepinephrine-noradrenaline-pediatric-drug-information/abstract-text/20200382/pubmed" id="20200382" target="_blank">20200382</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31010560">
<a name="31010560"></a>Dempsey E, Rabe H. The use of cardiotonic drugs in neonates. <i>Clin Perinatol</i>. 2019;46(2):273-290. doi:10.1016/j.clp.2019.02.010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norepinephrine-noradrenaline-pediatric-drug-information/abstract-text/31010560/pubmed" id="31010560" target="_blank">31010560</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2510208">
<a name="2510208"></a>Denkler KA, Cohen BE. Reversal of Dopamine Extravasation Injury With Topical Nitroglycerin Ointment. <i>Plast Reconstr Surg.</i> 1989;84(5):811-813.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norepinephrine-noradrenaline-pediatric-drug-information/abstract-text/2510208/pubmed" id="2510208" target="_blank">2510208</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Domonoske.1">
<a name="Domonoske.1"></a>Domonoske C. Appendix A: Common neonatal intensive care unit (NICU) medication guidelines. In: Eichenwald EC, Hansen AR, Martin CR, Stark AR. <i>Cloherty and Stark's Manual of Neonatal Care</i>. 8th edition. Lippincott Williams &amp; Wilkins; 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12143045">
<a name="12143045"></a>Duvoux C, Zanditenas D, Hézode C, et al. Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: a pilot study. <i>Hepatology</i>. 2002;36(2):374-380. doi:10.1053/jhep.2002.34343<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norepinephrine-noradrenaline-pediatric-drug-information/abstract-text/12143045/pubmed" id="12143045" target="_blank">12143045</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34276366">
<a name="34276366"></a>El-Desoki Mahmoud EI, Abdelaziz DH, Abd-Elsalam S, Mansour NO. Norepinephrine is more effective than midodrine/octreotide in patients with hepatorenal syndrome-acute kidney injury: a randomized controlled trial. <i>Front Pharmacol</i>. 2021;12:675948. doi:10.3389/fphar.2021.675948<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norepinephrine-noradrenaline-pediatric-drug-information/abstract-text/34276366/pubmed" id="34276366" target="_blank">34276366</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4004425">
<a name="4004425"></a>Elias AN, Vaziri ND, Maksy M. Plasma norepinephrine, epinephrine, and dopamine levels in end-stage renal disease. Effect of hemodialysis. <i>Arch Intern Med</i>. 1985;145(6):1013-1015.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norepinephrine-noradrenaline-pediatric-drug-information/abstract-text/4004425/pubmed" id="4004425" target="_blank">4004425</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Elmer.1">
<a name="Elmer.1"></a>Elmer J, Rittenberger JC. Initial assessment and management of the adult post-cardiac arrest patient. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 5, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33622380">
<a name="33622380"></a>Erstad BL, Barletta JF. Drug dosing in the critically ill obese patient: a focus on medications for hemodynamic support and prophylaxis. <i>Crit Care</i>. 2021;25(1):77. doi:10.1186/s13054-021-03495-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norepinephrine-noradrenaline-pediatric-drug-information/abstract-text/33622380/pubmed" id="33622380" target="_blank">33622380</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34605781">
<a name="34605781"></a>Evans L, Rhodes A, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. <i>Crit Care Med</i>. 2021;49(11):e1063-e1143<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norepinephrine-noradrenaline-pediatric-drug-information/abstract-text/34605781/pubmed" id="34605781" target="_blank">34605781</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.dor">
<a name="Expert.dor"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20956217">
<a name="20956217"></a>Field JM, Hazinski MF, Sayre MR, et al. Part 1: Executive Summary: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. <i>Circulation.</i> 2010;122(18)(suppl 3):640-56.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norepinephrine-noradrenaline-pediatric-drug-information/abstract-text/20956217/pubmed" id="20956217" target="_blank">20956217</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hochman.2020">
<a name="Hochman.2020"></a>Hochman JS, Reyentovich A. Prognosis and treatment of cardiogenic shock complicating acute myocardial infarction. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 29, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21097695">
<a name="21097695"></a>Hollenberg SM. Vasoactive drugs in circulatory shock. <i>Am J Respir Crit Care Med</i>. 2011;183(7):847-855. doi:10.1164/rccm.201006-0972CI<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norepinephrine-noradrenaline-pediatric-drug-information/abstract-text/21097695/pubmed" id="21097695" target="_blank">21097695</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15343024">
<a name="15343024"></a>Hollenberg SM, Ahrens TS, Annane D, et al. Practice parameters for hemodynamic support of sepsis in adult patients: 2004 update. <i>Crit Care Med.</i> 2004;32(9):1928-1948. doi:10.1097/01.ccm.0000139761.05492.d6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norepinephrine-noradrenaline-pediatric-drug-information/abstract-text/15343024/pubmed" id="15343024" target="_blank">15343024</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15192356">
<a name="15192356"></a>Hurst S, McMillan M. Innovative Solutions in Critical Care Units: Extravasation Guidelines. <i>Dimens Crit Care Nurs.</i> 2004;23(3):125-1258.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norepinephrine-noradrenaline-pediatric-drug-information/abstract-text/15192356/pubmed" id="15192356" target="_blank">15192356</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ISMP.1">
<a name="ISMP.1"></a>Institute for Safe Medication Practice (ISMP), Vermont Oxford Network. Standard Concentrations of Neonatal Drug Infusions. 2011. https://www.ismp.org/Tools/PediatricConcentrations.pdf
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28953318">
<a name="28953318"></a>Israelsen M, Krag A, Allegretti AS, et al. Terlipressin versus other vasoactive drugs for hepatorenal syndrome. <i>Cochrane Database Syst Rev</i>. 2017;9(9):CD011532. doi:10.1002/14651858.CD011532.pub2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norepinephrine-noradrenaline-pediatric-drug-information/abstract-text/28953318/pubmed" id="28953318" target="_blank">28953318</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26443610">
<a name="26443610"></a>Jeejeebhoy FM, Zelop CM, Lipman S, et al; American Heart Association Emergency Cardiovascular Care Committee, Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation, Council on Cardiovascular Diseases in the Young, and Council on Clinical Cardiology. Cardiac Arrest in Pregnancy: A Scientific Statement From the American Heart Association. <i>Circulation</i>. 2015;132(18):1747-1773. doi:10.1161/CIR.0000000000000300<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norepinephrine-noradrenaline-pediatric-drug-information/abstract-text/26443610/pubmed" id="26443610" target="_blank">26443610</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28528561">
<a name="28528561"></a>Khanna A, English SW, Wang XS, et al; ATHOS-3 Investigators. Angiotensin II for the treatment of vasodilatory shock. <i>N Engl J Med</i>. 2017;377(5):419-430. doi:10.1056/NEJMoa1704154<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norepinephrine-noradrenaline-pediatric-drug-information/abstract-text/28528561/pubmed" id="28528561" target="_blank">28528561</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20956230">
<a name="20956230"></a>Kleinman ME, Chameides L, Schexnayder SM, et al. Part 14: Pediatric Advanced Life Support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. <i>Circulation</i>. 2010;122(18)(suppl 3):876-908.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norepinephrine-noradrenaline-pediatric-drug-information/abstract-text/20956230/pubmed" id="20956230" target="_blank">20956230</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33837624">
<a name="33837624"></a>Kwong A, Kim WR, Kwo PY, Wang U, Cheng X. Feasibility and effectiveness of norepinephrine outside the intensive care setting for treatment of hepatorenal syndrome. <i>Liver Transpl</i>. 2021;27(8):1095-1105. doi:10.1002/lt.26065<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norepinephrine-noradrenaline-pediatric-drug-information/abstract-text/33837624/pubmed" id="33837624" target="_blank">33837624</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32049269">
<a name="32049269"></a>Lamontagne F, Richards-Belle A, Thomas K, et al; 65 trial investigators. Effect of reduced exposure to vasopressors on 90-day mortality in older critically ill patients with vasodilatory hypotension: a randomized clinical trial. <i>JAMA</i>. 2020;323(10):938-949. doi:10.1001/jama.2020.0930<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norepinephrine-noradrenaline-pediatric-drug-information/abstract-text/32049269/pubmed" id="32049269" target="_blank">32049269</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22568565">
<a name="22568565"></a>Lampin ME, Rousseaux J, Botte A, Sadik A, Cremer R, Leclerc F. Noradrenaline use for septic shock in children: doses, routes of administration and complications. <i>Acta Paediatr</i>. 2012;101(9):e426-430.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norepinephrine-noradrenaline-pediatric-drug-information/abstract-text/22568565/pubmed" id="22568565" target="_blank">22568565</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Levophed.1">
<a name="Levophed.1"></a>Levophed (norepinephrine) [prescribing information]. Lake Forest, IL: Hospira Inc; October 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Levophed.2">
<a name="Levophed.2"></a>Levophed (norepinephrine) [product monograph]. Kirkland, Québec, Canada: Pfizer Canada ULC; December 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29976291">
<a name="29976291"></a>Levy B, Clere-Jehl R, Legras A, et al. Epinephrine versus norepinephrine for cardiogenic shock after acute myocardial infarction. <i>J Am Coll Cardiol</i>. 2018;72(2):173-182. doi:10.1016/j.jacc.2018.04.051<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norepinephrine-noradrenaline-pediatric-drug-information/abstract-text/29976291/pubmed" id="29976291" target="_blank">29976291</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28073314">
<a name="28073314"></a>Lewis T, Merchan C, Altshuler D, Papadopoulos J. Safety of the peripheral administration of vasopressor agents. <i>J Intensive Care Med</i>. 2019;34(1):26-33. doi:10.1177/0885066616686035<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norepinephrine-noradrenaline-pediatric-drug-information/abstract-text/28073314/pubmed" id="28073314" target="_blank">28073314</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manaker.1">
<a name="Manaker.1"></a>Manaker S. Use of vasopressors and inotropes. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 29, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8404107">
<a name="8404107"></a>Martin C, Papazian L, Perrin G, Saux P, Gouin F. Norepinephrine or dopamine for the treatment of hyperdynamic septic shock?. <i>Chest</i>. 1993;103(6):1826-1831. doi: 10.1378/chest.103.6.1826<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norepinephrine-noradrenaline-pediatric-drug-information/abstract-text/8404107/pubmed" id="8404107" target="_blank">8404107</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2389659">
<a name="2389659"></a>Martin C, Saux P, Eon B, Aknin P, Gouin F. Septic shock: a goal-directed therapy using volume loading, dobutamine and/or norepinephrine. <i>Acta Anaesthesiol Scand</i>. 1990;34(5):413-417. doi:10.1111/j.1399-6576.1990.tb03114.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norepinephrine-noradrenaline-pediatric-drug-information/abstract-text/2389659/pubmed" id="2389659" target="_blank">2389659</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29110979">
<a name="29110979"></a>Medlej K, Kazzi AA, El Hajj Chehade A, et al. Complications from administration of vasopressors through peripheral venous catheters: an observational study. <i>J Emerg Med</i>. 2018;54(1):47-53. doi:10.1016/j.jemermed.2017.09.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norepinephrine-noradrenaline-pediatric-drug-information/abstract-text/29110979/pubmed" id="29110979" target="_blank">29110979</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20032025">
<a name="20032025"></a>Minzter BH, Johnson RF, Paschall RL, et al. The Diverse Effects of Vasopressors on the Fetoplacental Circulation of the Dual Perfused Human Placenta. <i>Anesth Analg</i>. 2010;110(3):857-862.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norepinephrine-noradrenaline-pediatric-drug-information/abstract-text/20032025/pubmed" id="20032025" target="_blank">20032025</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25203311">
<a name="25203311"></a>Nassar Junior AP, Farias AQ, D' Albuquerque LA, Carrilho FJ, Malbouisson LM. Terlipressin versus norepinephrine in the treatment of hepatorenal syndrome: a systematic review and meta-analysis. <i>PLoS One</i>. 2014;9(9):e107466. doi:10.1371/journal.pone.0107466<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norepinephrine-noradrenaline-pediatric-drug-information/abstract-text/25203311/pubmed" id="25203311" target="_blank">25203311</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Norepinephrine.1">
<a name="Norepinephrine.1"></a>Norepinephrine bitartrate in dextrose injection [prescribing information]. Deerfield, IL: Baxter Healthcare Corporation; June 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WG.1">
<a name="WG.1"></a>Norepinephrine bitartrate in sodium chloride injection [prescribing information]. Paramus, NJ: WG Critical Care LLC; October 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32925324">
<a name="32925324"></a>Pancaro C, Shah N, Pasma W, et al. Risk of major complications after perioperative norepinephrine infusion through peripheral intravenous lines in a multicenter study. <i>Anesth Analg</i>. 2020;131(4):1060-1065. doi:10.1213/ANE.0000000000004445<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norepinephrine-noradrenaline-pediatric-drug-information/abstract-text/32925324/pubmed" id="32925324" target="_blank">32925324</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Park.1">
<a name="Park.1"></a>Park, MK, Salamat M. Appendix E: Drugs used in pediatric cardiology. In: <i>Park's Pediatric Cardiology for Practitioners</i>. 7th ed. Elsevier Health Sciences; 2021: 477-492.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20956225">
<a name="20956225"></a>Peberdy MA, Callaway CW, Neumar RW, et al; American Heart Association. Part 9: post-cardiac arrest care: 2010 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. <i>Circulation</i>. 2010;122(18)(suppl 3):S768-S786. doi:10.1161/CIRCULATIONAHA.110.971002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norepinephrine-noradrenaline-pediatric-drug-information/abstract-text/20956225/pubmed" id="20956225" target="_blank">20956225</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22058104">
<a name="22058104"></a>Phillips MS. Standardizing I.V. Infusion Concentrations: National Survey Results. <i>Am J Health Syst Pharm</i>. 2011;68(22):2176-2182.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norepinephrine-noradrenaline-pediatric-drug-information/abstract-text/22058104/pubmed" id="22058104" target="_blank">22058104</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33049486">
<a name="33049486"></a>Prasanna N, Yamane D, Haridasa N, Davison D, Sparks A, Hawkins K. Safety and efficacy of vasopressor administration through midline catheters. <i>J Crit</i>
<i>Care</i>. 2021;61:1-4. doi:10.1016/j.jcrc.2020.09.024<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norepinephrine-noradrenaline-pediatric-drug-information/abstract-text/33049486/pubmed" id="33049486" target="_blank">33049486</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26724290">
<a name="26724290"></a>Radosevich JJ, Patanwala AE, Erstad BL. Norepinephrine dosing in obese and nonobese patients with septic shock. <i>Am J Crit Care</i>. 2016;25(1):27-32. doi:10.4037/ajcc2016667<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norepinephrine-noradrenaline-pediatric-drug-information/abstract-text/26724290/pubmed" id="26724290" target="_blank">26724290</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24420913">
<a name="24420913"></a>Reynolds PM, Maclaren R, Mueller SW, Fish DN, Kiser TH. Management of extravasation injuries: a focused evaluation of noncytotoxic medications. <i>Pharmacotherapy</i>. 2014;34(6):617-632. doi:10.1002/phar.1396<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norepinephrine-noradrenaline-pediatric-drug-information/abstract-text/24420913/pubmed" id="24420913" target="_blank">24420913</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28101605">
<a name="28101605"></a>Rhodes A, Evans LE, Alhazzani W, et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock: 2016. <i>Intensive Care Med.</i> 2017;43(3):304-377. doi:10.1007/s00134-017-4683-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norepinephrine-noradrenaline-pediatric-drug-information/abstract-text/28101605/pubmed" id="28101605" target="_blank">28101605</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28992392">
<a name="28992392"></a>Rizk MY, Lapointe A, Lefebvre F, Barrington KJ. Norepinephrine infusion improves haemodynamics in the preterm infants during septic shock. <i>Acta Paediatr</i>. 2018;107(3):408-413. doi:10.1111/apa.14112<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norepinephrine-noradrenaline-pediatric-drug-information/abstract-text/28992392/pubmed" id="28992392" target="_blank">28992392</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27744568">
<a name="27744568"></a>Rowcliff K, de Waal K, Mohamed AL, Chaudhari T. Noradrenaline in preterm infants with cardiovascular compromise. <i>Eur J Pediatr</i>. 2016;175(12):1967-1973. doi:10.1007/s00431-016-2794-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norepinephrine-noradrenaline-pediatric-drug-information/abstract-text/27744568/pubmed" id="27744568" target="_blank">27744568</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18305265">
<a name="18305265"></a>Russell JA, Walley KR, Singer J, et al; VASST Investigators. Vasopressin versus norepinephrine infusion in patients with septic shock. <i>N Engl J Med</i>. 2008;358(9):877-887. doi:10.1056/NEJMoa067373<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norepinephrine-noradrenaline-pediatric-drug-information/abstract-text/18305265/pubmed" id="18305265" target="_blank">18305265</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9342718">
<a name="9342718"></a>Sasse S, Kribs A, Vierzig A, Roth B. A staged protocol for the treatment of persistent pulmonary hypertension of the newborn. <i>Klin Padiatr</i>. 1997;209(5):301-307. doi:10.1055/s-2008-1043968<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norepinephrine-noradrenaline-pediatric-drug-information/abstract-text/9342718/pubmed" id="9342718" target="_blank">9342718</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18557715">
<a name="18557715"></a>Sharma P, Kumar A, Shrama BC, Sarin SK. An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response. <i>Am J Gastroenterol</i>. 2008;103(7):1689-1697. doi:10.1111/j.1572-0241.2008.01828.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norepinephrine-noradrenaline-pediatric-drug-information/abstract-text/18557715/pubmed" id="18557715" target="_blank">18557715</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31871244">
<a name="31871244"></a>Shenoi RP, Timm N; Committee on Drugs; Committee on Pediatric Emergency Medicine. Drugs Used to Treat Pediatric Emergencies. <i>Pediatrics</i>. 2020;145(1):e20193450.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norepinephrine-noradrenaline-pediatric-drug-information/abstract-text/31871244/pubmed" id="31871244" target="_blank">31871244</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22322237">
<a name="22322237"></a>Singh V, Ghosh S, Singh B, et al. Noradrenaline vs. terlipressin in the treatment of hepatorenal syndrome: a randomized study. <i>J Hepatol</i>. 2012;56(6):1293-1298. doi:10.1016/j.jhep.2012.01.012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norepinephrine-noradrenaline-pediatric-drug-information/abstract-text/22322237/pubmed" id="22322237" target="_blank">22322237</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36938775">
<a name="36938775"></a>Stefanos SS, Kiser TH, MacLaren R, Mueller SW, Reynolds PM. Management of noncytotoxic extravasation injuries: a focused update on medications, treatment strategies, and peripheral administration of vasopressors and hypertonic saline. <i>Pharmacotherapy</i>. 2023;43(4):321-337. doi:10.1002/phar.2794<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norepinephrine-noradrenaline-pediatric-drug-information/abstract-text/36938775/pubmed" id="36938775" target="_blank">36938775</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9928712">
<a name="9928712"></a>Stier PA, Bogner MP, Webster K, et al. Use of Subcutaneous Terbutaline to Reverse Peripheral Ischemia. <i>Am J Emerg Med</i>. 1999;17(1):91-94.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norepinephrine-noradrenaline-pediatric-drug-information/abstract-text/9928712/pubmed" id="9928712" target="_blank">9928712</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31698544">
<a name="31698544"></a>Tian DH, Smyth C, Keijzers G, et al. Safety of peripheral administration of vasopressor medications: a systematic review. <i>Emerg Med Australas</i>. 2020;32(2):220-227. doi:10.1111/1742-6723.13406<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norepinephrine-noradrenaline-pediatric-drug-information/abstract-text/31698544/pubmed" id="31698544" target="_blank">31698544</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18177443">
<a name="18177443"></a>Tourneux P, Rakza T, Abazine A, Krim G, Storme L. Noradrenaline for management of septic shock refractory to fluid loading and dopamine or dobutamine in full-term newborn infants. <i>Acta Paediatr</i>. 2008a;97(2):177-180.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norepinephrine-noradrenaline-pediatric-drug-information/abstract-text/18177443/pubmed" id="18177443" target="_blank">18177443</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18534241">
<a name="18534241"></a>Tourneux P, Rakza T, Bouissou A, Krim G, Storme L. Pulmonary circulatory effects of norepinephrine in newborn infants with persistent pulmonary hypertension. <i>J Pediatr</i>. 2008b;153(3):345-349.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norepinephrine-noradrenaline-pediatric-drug-information/abstract-text/18534241/pubmed" id="18534241" target="_blank">18534241</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18310626">
<a name="18310626"></a>Tremblay M, Lessard MR, Trépanier CA, et al. Stability of Norepinephrine Infusions Prepared in Dextrose and Normal Saline Solutions. <i>Can J Anaesth</i>. 2008;55(3):163-167.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norepinephrine-noradrenaline-pediatric-drug-information/abstract-text/18310626/pubmed" id="18310626" target="_blank">18310626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9120109">
<a name="9120109"></a>Tsubo T, Hashimoto Y, Araki I, Ishihara H, Matsuki A. Cortisol and catecholamine kinetics during continuous hemodiafiltration in patients with multiple organ dysfunction syndrome. <i>Intensive Care Med</i>. 1996;22(11):1176-1178. doi:10.1007/BF01709332<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norepinephrine-noradrenaline-pediatric-drug-information/abstract-text/9120109/pubmed" id="9120109" target="_blank">9120109</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20000886">
<a name="20000886"></a>Udy AA, Roberts JA, Boots RJ, Paterson DL, Lipman J. Augmented renal clearance: implications for antibacterial dosing in the critically ill. <i>Clin Pharmacokinet</i>. 2010;49(1):1-16. doi:10.2165/11318140-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norepinephrine-noradrenaline-pediatric-drug-information/abstract-text/20000886/pubmed" id="20000886" target="_blank">20000886</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27886982">
<a name="27886982"></a>Vadiei N, Daley MJ, Murthy MS, Shuman CS. Impact of norepinephrine weight-based dosing compared with non-weight-based dosing in achieving time to goal mean arterial pressure in obese patients with septic shock. <i>Ann Pharmacother</i>. 2017;51(3):194-202. doi:10.1177/1060028016682030<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norepinephrine-noradrenaline-pediatric-drug-information/abstract-text/27886982/pubmed" id="27886982" target="_blank">27886982</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28923988">
<a name="28923988"></a>van Diepen S, Katz JN, Albert NM, et al; American Heart Association Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; Council on Quality of Care and Outcomes Research; Mission: Lifeline. Contemporary management of cardiogenic shock: a scientific statement from the American Heart Association. <i>Circulation</i>. 2017;136(16):e232-e268. doi:10.1161/CIR.0000000000000525<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norepinephrine-noradrenaline-pediatric-drug-information/abstract-text/28923988/pubmed" id="28923988" target="_blank">28923988</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22478966">
<a name="22478966"></a>Walker SE, Law S, Garland J, Fung E, Iazzetta J. Stability of norepinephrine solutions in normal saline and 5% dextrose in water. <i>Can J Hosp Pharm</i>. 2010 ;63(2):113-118. doi:10.4212/cjhp.v63i2.896<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norepinephrine-noradrenaline-pediatric-drug-information/abstract-text/22478966/pubmed" id="22478966" target="_blank">22478966</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10503181">
<a name="10503181"></a>Wang L, Zhang W, Zhao Y. The Study of Maternal and Fetal Plasma Catecholamines Levels During Pregnancy and Delivery. <i>J Perinat Med</i>. 1999;27(3):195-198.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norepinephrine-noradrenaline-pediatric-drug-information/abstract-text/10503181/pubmed" id="10503181" target="_blank">10503181</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32032273">
<a name="32032273"></a>Weiss SL, Peters MJ, Alhazzani W, et al. Surviving Sepsis Campaign International Guidelines for the Management of Septic Shock and Sepsis-Associated Organ Dysfunction in Children. <i>Pediatr Crit Care Med</i>. 2020;21(2):e52-e106. doi:10.1097/PCC.0000000000002198<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norepinephrine-noradrenaline-pediatric-drug-information/abstract-text/32032273/pubmed" id="32032273" target="_blank">32032273</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1447671">
<a name="1447671"></a>Wong AF, McCulloch LM, Sola A. Treatment of Peripheral Tissue Ischemia With Topical Nitroglycerin Ointment in Neonates. <i>J Pediatr</i>. 1992;121(6):980-983.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norepinephrine-noradrenaline-pediatric-drug-information/abstract-text/1447671/pubmed" id="1447671" target="_blank">1447671</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 12650 Version 412.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
